Table 1.

Patterns of serum antibodies following pediatric GII.17 infections.

Subject ID	ORF1/2 sequencing from stool	Post-infection serum antibodies1
		Binding		Blockade
		Specificity	EC50 titer2	Specificity	IC50 titer3
62	II	I,II, IIIb	287,210,150	I	979
132	II	I,II, IIIb	481,389,406	I	479
317	II	I,II, IIIb	235,192,113	I	460
208	IIIb	I,II, IIIb	350,281,554	IIIb	625
263	IIIb	I,II, IIIb	292,518,1252	IIIb	2974
369	IIIb	I,II, IIIb	563,332,1502	I, IIIb	406, 7290
434	IIIb	I,II, IIIb	333,357,366	I, IIIb	500, 1843

¹Sera were collected at different times post infection which limits direct comparisons between subjects and may impact the relative titer between clusters as other infections may have occurred prior to GII.17 infection and between the symptomatic GII.17 infection and follow up sera collections.

²Binding titers with respect to indicated specificities. Value indicated is reciprocal of the serum dilution at half maximum binding (50% effective concentration, EC₅₀) for EIA. Assay cutoff is EC₅₀ < 50.

³Blockade titers with respect to indicated specificities. Value indicated is reciprocal of the serum dilution at half maximum blockade activity (50% inhibitory concentration, IC₅₀). Assay cutoff is IC₅₀ < 20.